Neil Dahiya

Emcure Pharma’s SAKHI Diabetes Awareness Initiative Earns Spot in Asia Book of Records

Emcure Pharmaceuticals, a prominent player in the women’s healthcare sector, celebrated a remarkable achievement on World Diabetes Day by securing a place in the Asia Book of Records. The company orchestrated the largest virtual campaign focused on women’s diabetes awareness, […]

Emcure Pharma’s SAKHI Diabetes Awareness Initiative Earns Spot in Asia Book of Records Read More »

Alnylam Details Results from Early Phase 1 Trial of Nucresiran, Highlighting Prolonged TTR Reduction Post-Single Dose

**Alnylam Pharmaceuticals, Renowned RNAi Therapy Leader, Unveils Promising Phase 1 Outcomes for Nucresiran** Alnylam Pharmaceuticals, a front-runner in the field of RNA interference (RNAi) therapeutics, disclosed the latest findings from its phase 1 research on nucresiran (previously known as ALN-TTRsc04),

Alnylam Details Results from Early Phase 1 Trial of Nucresiran, Highlighting Prolonged TTR Reduction Post-Single Dose Read More »

WATCHMAN FLX Device Outperforms Oral Anticoagulants in Bleed Risk Reduction After Cardiac Ablation: OPTION Trial Results

Boston Scientific Corporation unveiled promising outcomes from the OPTION global clinical study involving the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device, sharing three years of primary endpoint results. The study, which contrasted the device with initial oral anticoagulation (OAC)

WATCHMAN FLX Device Outperforms Oral Anticoagulants in Bleed Risk Reduction After Cardiac Ablation: OPTION Trial Results Read More »

BioCryst Introduces Orladeyo in Ireland for Regular Prevention of HAE Recurrent Attacks in Those Aged 12 and Up

BioCryst Pharmaceuticals, Inc., a leading biotech firm, revealed that Ireland’s Health Services Executive (HSE) has endorsed Orladeyo (berotralstat) for the regular prevention of repeated hereditary angioedema (HAE) attacks in suitable patients aged 12 and above. This endorsement enables Irish HAE

BioCryst Introduces Orladeyo in Ireland for Regular Prevention of HAE Recurrent Attacks in Those Aged 12 and Up Read More »

LIfT BioSciences Establishes New Subsidiary in Galway, Ireland, Enhancing Manufacturing and Clinical Operations

LIfT BioSciences, a leading-edge biotech firm gearing up to kick off clinical trials for its novel allogeneic innate cell therapy, has unveiled its latest expansion in manufacturing and clinical activities with the establishment of its Galway-based subsidiary, Eolaíocht Bhitheach LIfT

LIfT BioSciences Establishes New Subsidiary in Galway, Ireland, Enhancing Manufacturing and Clinical Operations Read More »

EnteroBiotix Completes Phase 2 TrIuMPH Patient Enrollment for EBX-102-02 in IBS Study

**EnteroBiotix, Ltd.**, a biotechnology firm at the clinical stage, specializing in advanced microbiome therapeutics, has announced the fulfillment of participant recruitment for their phase 2 TrIuMPH clinical trial. This study is evaluating the safety, tolerability, and effectiveness of EBX-102-02, their

EnteroBiotix Completes Phase 2 TrIuMPH Patient Enrollment for EBX-102-02 in IBS Study Read More »

Molbio Empowers Azerbaijan’s Eco-Friendly TB Initiative at COP29 with Cutting-Edge Diagnostic Support

In a strategic push to address tuberculosis (TB) while considering the impacts of climate change, Molbio Diagnostics, a pioneer in global healthcare innovation, has made a significant donation of advanced TB screening and diagnostic tools to Azerbaijan’s Ministry of Health.

Molbio Empowers Azerbaijan’s Eco-Friendly TB Initiative at COP29 with Cutting-Edge Diagnostic Support Read More »

China NMPA Grants Priority Review for Ascentage Pharma’s Lisaftoclax, a Novel Bcl-2 Inhibitor for r/r CLL/SLL

Ascentage Pharma, an international biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments addressing worldwide unmet medical needs, particularly in cancer, has announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted

China NMPA Grants Priority Review for Ascentage Pharma’s Lisaftoclax, a Novel Bcl-2 Inhibitor for r/r CLL/SLL Read More »